RU2015134560A - Кристаллическая форма vsn16 - Google Patents
Кристаллическая форма vsn16 Download PDFInfo
- Publication number
- RU2015134560A RU2015134560A RU2015134560A RU2015134560A RU2015134560A RU 2015134560 A RU2015134560 A RU 2015134560A RU 2015134560 A RU2015134560 A RU 2015134560A RU 2015134560 A RU2015134560 A RU 2015134560A RU 2015134560 A RU2015134560 A RU 2015134560A
- Authority
- RU
- Russia
- Prior art keywords
- crystalline form
- form according
- compound
- crystalline
- ray powder
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 239000012458 free base Substances 0.000 claims 5
- 208000008238 Muscle Spasticity Diseases 0.000 claims 4
- 206010000059 abdominal discomfort Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000018198 spasticity Diseases 0.000 claims 4
- 208000029578 Muscle disease Diseases 0.000 claims 3
- 208000021642 Muscular disease Diseases 0.000 claims 3
- 206010044565 Tremor Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000002178 crystalline material Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1300903.0A GB201300903D0 (en) | 2013-01-18 | 2013-01-18 | Crystalline Form |
| GB1300903.0 | 2013-01-18 | ||
| PCT/GB2014/050127 WO2014111720A1 (en) | 2013-01-18 | 2014-01-17 | Crystalline form of vsn16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015134560A true RU2015134560A (ru) | 2017-02-28 |
Family
ID=47843537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015134560A RU2015134560A (ru) | 2013-01-18 | 2014-01-17 | Кристаллическая форма vsn16 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9682924B2 (https=) |
| EP (1) | EP2945619B1 (https=) |
| JP (1) | JP2016505036A (https=) |
| CN (1) | CN105142626A (https=) |
| CA (1) | CA2897524A1 (https=) |
| GB (1) | GB201300903D0 (https=) |
| NZ (1) | NZ630795A (https=) |
| RU (1) | RU2015134560A (https=) |
| WO (1) | WO2014111720A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3256112A1 (en) * | 2015-02-13 | 2017-12-20 | Canbex Therapeutics Limited | Compounds for treating disorders associated with bk channel modulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0403864D0 (en) * | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| GB0903956D0 (en) | 2009-03-06 | 2009-04-22 | Ucl Business Plc | Process |
-
2013
- 2013-01-18 GB GBGB1300903.0A patent/GB201300903D0/en not_active Ceased
-
2014
- 2014-01-17 US US14/760,592 patent/US9682924B2/en active Active
- 2014-01-17 CA CA2897524A patent/CA2897524A1/en not_active Abandoned
- 2014-01-17 NZ NZ630795A patent/NZ630795A/en not_active IP Right Cessation
- 2014-01-17 EP EP14702299.0A patent/EP2945619B1/en active Active
- 2014-01-17 RU RU2015134560A patent/RU2015134560A/ru not_active Application Discontinuation
- 2014-01-17 WO PCT/GB2014/050127 patent/WO2014111720A1/en not_active Ceased
- 2014-01-17 CN CN201480013204.7A patent/CN105142626A/zh active Pending
- 2014-01-17 JP JP2015553165A patent/JP2016505036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014111720A1 (en) | 2014-07-24 |
| GB201300903D0 (en) | 2013-03-06 |
| EP2945619B1 (en) | 2019-05-08 |
| US20150353476A1 (en) | 2015-12-10 |
| US9682924B2 (en) | 2017-06-20 |
| CA2897524A1 (en) | 2014-07-24 |
| CN105142626A (zh) | 2015-12-09 |
| EP2945619A1 (en) | 2015-11-25 |
| JP2016505036A (ja) | 2016-02-18 |
| NZ630795A (en) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| CN102336801B (zh) | 醋酸阿比特龙多晶型物和药用组合物 | |
| JP2020514291A (ja) | Ｒａｄ１９０１−２ｈｃｌの多形性形態 | |
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2018503662A5 (https=) | ||
| MX2012013345A (es) | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. | |
| KR20230038229A (ko) | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 | |
| JP5654462B2 (ja) | 貧溶媒添加法による２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法 | |
| CA3030043C (en) | Rotigotine behenate, preparation method and use thereof | |
| CN106543072A (zh) | 匹莫范色林化合物 | |
| JP2006151999A5 (https=) | ||
| JP2019523297A5 (https=) | ||
| CN105061420B (zh) | 一种jak抑制剂的晶型及其制备方法和应用 | |
| CN104961733A (zh) | 雷迪帕韦新晶型及其制备方法 | |
| CN106117214A (zh) | 依鲁替尼新晶型及其制备方法 | |
| RU2015134560A (ru) | Кристаллическая форма vsn16 | |
| JP2019529553A5 (https=) | ||
| CN105503717A (zh) | 一种苹果酸卡博替尼化合物及其药物组合物 | |
| CN106543124A (zh) | 达格列净化合物 | |
| CN105859691A (zh) | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 | |
| CN106146498A (zh) | 一种新的利格列汀化合物 | |
| JP2016505036A5 (https=) | ||
| TW202306954A (zh) | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 | |
| CN106916157A (zh) | 取代的氨基吡喃衍生物的晶型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180827 |